SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network (AVT) is gaining significant community attention driven by its strategic TechSAFE partnership and the formal incorporation of its DAO in the UAE with a new advisor to expand its regional presence. Traders are actively discussing its enterprise-grade technology, Polkadot integration, and low market cap, anticipating a potential breakout with increased volume and new exchange listings.

JFrog Ltd. engages in the provision of an end-to-end, hybrid, universal development operations platform that powers and controls the software supply chain, which enables organizations to continuously and securely deliver software updates across any system. It operates through the following geographical segments: United States, Israel, India, and Rest of World. The firm is also involved in creating software delivered without friction from developer to device. The company was founded by Frederic Simon, Shlomi Ben Haim, and Yoav Landman in 2008 and is headquartered in Sunnyvale, CA.

JFrog Ltd

A notable sell-off in JFrog shares is sparking intense community discussion, with traders debating the implications of Anthropic's new Claude Code Security on the DevSecOps sector, while some analysts view the sharp decline as an exaggerated market reaction.

What are Mirrored Assets? MIR is the governance token of Mirror Protocol, a synthetic assets protocol built by Terraform Labs (TFL) on the Terra blockchain.  Mirror Protocol is decentralized from day 1, with the on-chain treasury and code changes governed by holders of the MIR token. TFL has no intention of keeping or selling MIR tokens, and there are no admin keys or special access privileges granted. The intent for this is to be a completely decentralized, community-driven project.  Mirrored assets are blockchain tokens that behave like ""mirror"" versions of real-world assets by reflecting the exchange prices on-chain. They give traders the price exposure to real assets while enabling fractional ownership, open access and censorship resistance as any other cryptocurrency. Unlike traditional tokens which serve to represent a real, underlying asset, mAssets are purely synthetic and only capture the price movement of the corresponding asset.

Mirror Protocol

Mirror Protocol ($MIR) is trending with a significant price pump, sparking active community speculation about its potential for explosive gains and its strong connection to the Terra ecosystem, as many anticipate its movement often precedes or accompanies a rally in $LUNC.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

The Sweat Economy ($SWEAT) is trending as its move-to-earn utility continues to engage users, allowing them to earn crypto through physical activity; despite experiencing significant price declines, the community remains active, discussing its long-term potential and viewing current valuations as a buying opportunity.

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech Inc - 9.375% PRF PERPETUAL USD 25 - Ser A

Fortress Biotech's preferred shares ($FBIOP) are trending as the FDA approval of CUTX-101 and its associated Priority Review Voucher (PRV) bring anticipated cash flow, prompting community discussion around the reinstatement of suspended dividends and the significant valuation disconnect with its common stock ($FBIO).

The Descartes Systems Group, Inc. engages in the provision of on-demand, software-as-a-service solutions focused on improving the productivity, performance and security of logistics-intensive businesses. It uses modular, software-as-a-service solutions to route, schedule, track and measure delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world's largest, collaborative multimodal logistics community. The company was founded on May 22, 1981 and is headquartered in Waterloo, Canada.

Descartes Systems Group Inc

Descartes Systems Group is trending following strong Q3 financial results, marked by an EPS beat and revenue growth, coupled with strategic acquisitions like Finale, which are driving positive sentiment. The community is actively discussing the company's consistent execution and expanding cloud logistics footprint, leading to renewed analyst upgrades and buy ratings within the dynamic supply chain sector.

Selective Insurance Group, Inc. is an insurance holding company, which engages in the provision of property and casualty insurance products. It operates through the following segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. The Standard Commercial Lines segment offers insurance products and services to commercial customers, such as non-profit organizations and local government agencies. The Standard Personal Lines segment consists of insurance products and services, including flood insurance coverage. The E&S Lines segment includes insurance products and services provided to customers who have not obtained coverage in the standard marketplace. The Investments segment refers to premiums collected by various segments and engages in the issuance of debt and equity securities. The company was founded by Daniel L. B. Smith in 1926 and is headquartered in Branchville, NJ.

Selective Insurance Group Inc.

Selective Insurance is trending as the community weighs its latest financial updates, including shareholder returns and long-term guidance, against detailed risk factor disclosures regarding catastrophe, tech competition, and regulatory scrutiny. The mixed analyst ratings and active options trading further reflect diverse investor perspectives on the insurer's outlook.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences faces intense market debate after its Phase 2 schizophrenia candidate showed positive results primarily at a lower dose, sparking significant stock volatility and skepticism despite positive top-line data. Amidst this, the community is weighing the company's strong Ingrezza sales and late-stage pipeline against recent disappointing earnings guidance and ongoing speculation about potential M&A.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

FDA approval of Vanda Pharmaceuticals' Bysanti for bipolar I disorder and schizophrenia has ignited strong community interest, marking the company's second major drug approval in months. Discussions are centered on Bysanti's patent protection until 2044, which positions VNDA as a prime buyout target for major pharmaceutical companies and fuels expectations for a significant valuation rerating and potential short squeeze.

Dollar General Corp. engages in the operation of merchandise stores. Its offerings include food, snacks, health and beauty aids, cleaning supplies, basic apparel, housewares, and seasonal items. It sells brands including Clorox, Energizer, Procter & Gamble, Hanes, Coca-Cola, Mars, Unilever, Nestle, Kimberly-Clark, Kellogg's, General Mills, and PepsiCo. The company was founded by J. L. Turner and Hurley Calister Turner Sr. in 1939 and is headquartered in Goodlettsville, TN.

Dollar General Corp.

Dollar General is trending as its recent robust earnings beat and raised full-year guidance, coupled with an expanded Uber Eats partnership, suggest strong operational momentum and a compelling value proposition to budget-conscious consumers. The community views DG as a resilient play, attracting a broader customer base amid economic shifts and benefiting from initiatives like shrink reduction and store remodels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) have earned a consensus recommendation of "Buy" from the seven analysts that are covering the company, MarketBeat Ratings...

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8% - What's Next?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8% - Time to Sell...

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8% - Here's Why

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 3.8% - What's Next...

Cantor Fitzgerald Raises Eupraxia Pharmaceuticals (NASDAQ:EPRX) Price Target to $19.00

Cantor Fitzgerald upped their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an "overweight" rating in a research report on Thursday...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of "Buy" from Analysts

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven analysts that are covering the stock, Marketbeat.com reports. One...

Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Grows By 138.8%

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 1,311,773...

Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus

Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission in EoE patients, with no serious safety issues reported.read more...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 30.1% in December

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totaling 549,299 shares, an increase of...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Buy" by Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) have been assigned an average recommendation of "Buy" from the seven ratings firms that are covering the firm, MarketBeat...

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

Current Price	$8.50
Prev Close	$8.12
Open	$8.13
Dividend Yield	0.00%
50-Day Moving Average	$7.88
Beta	0.50
Avg. Volume	172,810.50
PE Ratio	-9.78

52-Week High	$9.32
52-Week Low	$2.68
Market Capitalization	$430.51M
EPS (Annual)	-$0.7516
Price to Book	7.37
Revenue Per Employee	N/A

EPRX
Eupraxia Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest EPRX News

EPRXEupraxia Pharmaceuticals Inc